P124 PILOT STUDY OF DIFFERENTIALLY EXPRESSED GENES IN OSTEOARTHRITIC AND OSTEOPOROTIC BONE USING MICROARRAYS  by Allstaff, A.J. et al.
S78 Poster Presentations
Osteoprotegerin (OPG) gene expression. Animal models of OA
pathogenesis have shown that changes in subchondral trabec-
ular bone precede those of articular cartilage, and that altered
joint mechanics produced by this periarticular bone remodelling
may thus cause the cartilage and joint changes of OA. We hy-
pothesized that subchondral and trabecular bone densities were
increased in OA bone relative to age-matched cadaveric controls.
Methods: We compared the bony changes in the human tib-
ial plateau from samples taken at total knee arthroplasty (TKA,
n=15) against those from cadaveric controls (n=8). Micro com-
puted tomography (micro-CT) was used to define and quantify
bone changes, and these data were coupled with the molecular
expression (by "in-situ" hybridization) of peptide factors known to
mediate bone remodeling.
Results: "In-situ" hybridization of digoxygenase (DIG)-labelled
OPG riboprobes showed selective uptake in osteoblasts, but
not osteocytes or osteoclasts in TKA bone. Staining of DIG-
labelled OPG was particularly evident in activated osteoblasts
involved in bone adaptive/sclerotic processes. Using micro-CT,
subchondral OA bone samples were significantly different from
cadaveric controls for subchondral bone thickness, bone volume,
and trabecular thickness.
Conclusions: These data suggest that OPG expression by
osteoblasts may precipitate the bony hypertrophy of end-stage
OA. Thus, early modulation of the RANKL/OPG axis may provide
hope for halting the sclerotic bone changes leading to end-stage
OA.
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Purpose: The aim of this pilot study was to determine whether
gene arrays could identify key regulatory genes in bone, particu-
larly those that may be important for the bone proliferation seen
in osteoarthritis (OA). To do this we investigated differential gene
expression in osteoblasts from patients with either osteoporosis
(OP) (low bone mass phenotype) or OA (excess, hypomineral-
ized bone), which could then be validated in in-vitro models of
osteoblast differentiation. The differences in bone quality indicate
a change at the cellular level but little is known of differences in
osteoblast phenotype and gene expression between OA and OP.
Methods: Microarrays were used to analyse differences in gene
expression between primary osteoblasts derived from osteo-
porotic or osteoarthritic bone. Femoral heads were obtained
from two patients undergoing a hip replacement due to OA and
two patients following a fractured neck of femur attributed to
OP. Osteoblast-like cells were cultured from fragments of tra-
becular bone. Total RNA was extracted by TRIZol and further
purified via Qiagen RNeasy columns. Samples were hybridised
to Affymetrix HG-U133A Genechips and data analysed using
GCOS and Netaffyx software. Gene expression differences were
measured as fold increase or decrease in pair-wise comparisons
between each OP and OA sample. Gene ontology and functional
annotation clustering was performed using DAVID 2006 (NIAID).
Results: One hundred and nineteen genes displayed a >2-
fold difference in expression in at least 3 out of 4 pair-wise
comparisons, with 82 genes up regulated and 37 down-regulated
in OA samples compared with OP. Many of the genes identified
have been little studied; notable exceptions were IGF1, cyclin D2,
alkaline phosphatase (ALPL) and IL8 that were all more highly
expressed in OA. IL6ST (gp130) was lower in OA compared to
OP.11 genes associated with the extracellular matrix were all
expressed at higher levels in OA, and 13 genes were associated
with the immune response. Six genes were associated with
increased angiogenesis, all of which were more highly expressed
in the OA samples.
Conclusions: These pilot data confirm the value of microarray
analysis for identifying families of genes that affect processes
such as matrix formation and degradation, angiogenesis and im-
mune responses. Further studies with more samples will confirm
the most important of the expressed genes, but these prelimi-
nary data fit with the hypothesis of OA including an inflammatory
process. Osteoarthritic bone is disorganized and increased in
quantity, whereas osteoporotic bone is more normally organized
but reduced in quantity. This is reflected in greater gene ex-
pression for matrix components. The elevated levels of IGF 1,
cyclin D2, IL8 and alkaline phosphatase are all indicative of
greater bone formation and turnover. GP130 is integral to sev-
eral IL6-family signalling pathways, which have profound effects
on bone metabolism - affecting both osteoblasts and osteo-
clasts. Increased angiogenic-related factors have been reported
in a previous study of OA bone and support an inflammatory
component to the disease. Identifying key factors regulating tis-
sue hypertrophy in OA and bone loss in OP may lead to new
approaches for controlling the disease processes.
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Purpose: Patients with primary osteoporosis (N=123; 6 men
and 117 women) who had received the therapy for 48 weeks
with risedronate (RIS), alfacalcidol (VD3), and menatetrenone
(VK2) (reported at ASBMR 2005) were subsequently treated
with either RIS alone, RIS + VD3, or RIS + VK2 for another 48
weeks. Changes in bone metabolism markers and bone mineral
density (BMI) were prospectively assessed to compare these
three regimens.
Methods: There were 26 evaluable subjects from the RIS group
(2.5 mg/day), 23 from the RIS + VD3 group (0.5 μg/day), and
18 from the RIS + VK2 group (45 mg/day). Bone metabolism
markers [urinary and blood NTX, urinary DPD, blood osteocalcin
(OC), and bone alkaline phosphatase (BAP)] were measured at
the start of therapy, as well as after 4, 12, 24, 36, and 48 weeks
of the therapy. In addition, the lumbar BMD was measured by
DXA at the start of therapy as well as after 12, 24, and 48 weeks
of therapy. Lumbar X-ray films were examined for the presence of
new fractures, and the occurrence of serious adverse events was
also investigated. The t-test was used for intergroup comparison,
and the level of significance was set at p<0.05.
Results: Bone resorption markers (NTX and DPD) only showed
a slight decrease in the RIS group, but showed a marked de-
crease in the RIS + VD3 and RIS + VK2 groups. The inhibition
of bone resorption was maintained until completion of 48 weeks
of treatment in the combined therapy groups. Interestingly, the
early change (percent decrease from the baseline) was more
prominent in the RIS + VK2 group than in the RIS + VD3 group.
However, there was no significant difference among the 3 groups
with respect to the percent change of NTX at 24 weeks of ther-
apy. The bone formation markers (OC and BAP) did not show
any definitive changes, except for a decrease of BAP in the RIS
group. The percent change of BMD was + 1.4% in the RIS group,
+3.9% in the RIS + VD3 group, and + 2.9% in the RIS + VK2
group, showing no significant difference among the 3 groups. Oc-
